CTNNA2 and cancer: Genome-wide methylation-associated biomarkers were involved in the pathways of neurodegeneration-multiple diseases (13%), cancer-related pathways (DCC, RASSF1, WNT1, CTNNA2; 13%), and Hippo, calcium signalling, cell adhesion and immune system-related pathways (all 10%) (Figure 3D).